Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
BAALC was identified by gene expression studies in patients with acute myeloid leukemia (AML). Additionally we are shipping BAALC Proteins (9) and BAALC Kits (4) and many more products for this protein.
Showing 10 out of 46 products:
Human Polyclonal BAALC Primary Antibody for EIA, WB - ABIN452776
Kuila, Sahoo, Kumari, Biswas, Patnaik, Pattnayak, Biswas, Chakraborty: EVI1, BAALC and AME: prevalence of the secondary mutations in chronic and accelerated phases of chronic myeloid leukemia patients from eastern India. in Leukemia research 2009
Show all 2 references for ABIN452776
Human Polyclonal BAALC Primary Antibody for ELISA, WB - ABIN250807
Satoskar, Tanner, Weinstein, Qualman, de la Chapelle: Baalc, a marker of mesoderm and muscle. in Gene expression patterns : GEP 2005
Human Monoclonal BAALC Primary Antibody for ELISA, WB - ABIN529108
Ikeda, Ageta, Tsuchida, Yamada: iTRAQ-based proteomics reveals novel biomarkers of osteoarthritis. in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2013
BAALC and ERG (show ERG Antibodies) genes are specific significant molecular markers in acute myeloid leukemia (show BCL11A Antibodies) disease progression, response to treatment and survival.
demonstrated that BAALC blocks ERK (show EPHB2 Antibodies)-mediated monocytic differentiation of acute myeloid leukemia (show BCL11A Antibodies) cells by trapping Kruppel-like factor 4 (KLF4 (show KLF4 Antibodies)) in the cytoplasm and inhibiting its function in the nucleus
combined determination of both miR (show MLXIP Antibodies)-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers
study indicates that overexpression of BAALC serves as an independent prognostic biomarker in acute myeloid leukemia (show BCL11A Antibodies)
Evaluating WT1 (show WT1 Antibodies) and BAALC gene expression at diagnosis may improve standard risk stratification and possibly refine the therapeutic approach for Myelodysplastic Syndromes patients.
Thus low MDR1 (show TBC1D9 Antibodies)/low BAALC expression identifies a subgroup of intermediate cytogenetic risk AML (show RUNX1 Antibodies) patients with a remarkably good long-term outcome achieved by chemotherapy alone.
miR (show MLXIP Antibodies)-3151 introns within BAALC have roles in driving leukemogenesis by deregulating the TP53 (show TP53 Antibodies) pathway
Higher BAALC expression and FLT3 (show FLT3 Antibodies)-ITD mutation, both individually and in combination, were associated with worse survival outcomes in CN-AML (show RUNX1 Antibodies), and this was also applicable in NPM1 (show NPM1 Antibodies)-mutated CN-AML (show RUNX1 Antibodies), known as a favorable-risk group.
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia (show BCL11A Antibodies) patients.
higher post-HSCT BAALC and WT1 (show WT1 Antibodies) expressions in patients with CBF (show CEBPZ Antibodies)-AML (show RUNX1 Antibodies) may be good markers of minimal residual disease for the prediction of survival and relapse after HSCT.
BAALC/Baalc is a marker of the mesodermal lineage, especially muscle.
This gene was identified by gene expression studies in patients with acute myeloid leukemia (AML). The gene is conserved among mammals and is not found in lower organisms. Tissues that express this gene develop from the neuroectoderm. Multiple alternatively spliced transcript variants that encode different proteins have been described for this gene\; however, some of the transcript variants are found only in AML cell lines.
brain and acute leukemia cytoplasmic protein
, brain and acute leukemia, cytoplasmic